The Medicine Maker Power List 2026 Celebrates 60 Leaders Driving Pharmaceutical Innovation Across Modalities
核心洞察
The Medicine Maker (搜索)'s Power List 2026 features 60 individuals across Small Molecules, Biopharma, and Advanced Medicines categories, each with a ranked Top 10.
New drug discovery technologies, including molecular glues and protein degraders, are expanding small molecule capabilities while cell therapies advance into solid tumors and autoimmune diseases.
The list highlights leaders tackling key industry challenges such as demonstrating value in capital-constrained markets and improving manufacturability of advanced therapies.
The Medicine Maker (搜索) has unveiled its Power List 2026, recognizing 60 inspirational individuals who are driving progress across the pharmaceutical landscape. The annual list, determined through community nominations and an expert judging panel, celebrates leaders across three distinct categories: Small Molecules, Biopharma, and Advanced Medicines, with 20 honorees in each category and a ranked Top 10 within each group.
The 2026 edition arrives at a moment of remarkable scientific momentum. New drug discovery technologies, greater biomolecular understanding of disease, and manufacturing advances are powering progress across a range of modalities. Molecular glues and protein degraders are pushing the boundaries of what was thought possible in small molecules, while cell therapies are expanding into solid tumors and even autoimmune diseases.
"It is hard not to get excited about the potential suite of effective therapies available for physicians and patients in the not-too-distant future," the publication notes in its announcement.
Navigating Industry Headwinds
Despite the scientific optimism, the Power List also casts a spotlight on the significant challenges facing the field. Key questions loom over the industry: Can leaders demonstrate value to investors in today's capital-constrained environment? Can the field find a way for different modalities to coexist as part of a mixed ecosystem? Can advanced therapies embrace manufacturability- and access-by-design models?
These questions underscore the dual mandate facing today's pharmaceutical leaders—advancing cutting-edge science while ensuring commercial viability and patient access.
A Community-Driven Recognition
As in previous years, the Power List is shaped by the broader pharmaceutical community. Nominations are submitted by readers and colleagues, and a panel of expert judges makes the final selections. The publication describes the list as a celebration of "the individuals working hard, pushing boundaries, and inspiring others to find the answers" to the field's most pressing challenges.
The full Power List 2026, including detailed profiles of all 60 honorees, is available on The Medicine Maker (搜索)'s website.